Shanghai And Hong Kong News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Shanghai and hong kong. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Shanghai And Hong Kong Today - Breaking & Trending Today

The first Shanghai-Hong Kong Entrepreneurs Roundtable was held in Shanghai to deepen economic and trade cooperation between the chambers of commerce of the two places

Shanghai and Hong Kong have maintained close economic and trade exchanges for a long time. The two sides will establish a working mechanism to enhance cooperation and exchanges. Shanghai-Hong Kong cooperation mechanism will continue to be upgraded, and there will be versions 2.0 and 3.0. Hong Kong has become an important force in the construction of the "Belt and Road" and an important window for Shanghai enterprises to "go global", says Tang Liang, vice president of Shanghai General Chamber of Commerce. ....

Hong Kong , Zhongxin Wanghai , Zhou Minhao , Cai Guanshen , Litang Liang , United Front Work Department , Aosheng Group Co Ltd , International Commerce , Shanghai Chamber , Hong Kong Xinhua Group , Shanghai Council For The Promotion Of International , Reporter Fan Yubin , Shanghai General Chamber , Hong Kong Chinese General Chamber , Shanghai Hong Kong Stock Connect , Shanghai Hong Kong Co Operation , Hong Kong , Shanghai Hong Kong , Chinese General Chamber , Shanghai Council , International Trade , Shanghai Hong Kong Economic , Trade Co Operation Conference , Hong Kong Entrepreneurs , Standing Committee , Shanghai Municipal Party Committee ,

Antengene Announces NDA Submission for XPOVIO in Indonesia

SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications (NDAs) for XPOVIO (selinexor) to the Indonesia National Agency of Drug and Food Control (BPOM) for the treatment of relapsed/refractory multiple myeloma (R/R MM) and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). In Q4 2022, Antengene also submitted NDAs for XPOVIO in Malaysia and Thailand. "In just six months, we have submitted NDAs for XPOVIO in three ASEAN countries, Malaysia, Thailand and Indonesia, supporting our plans to expand commercial presence in the APAC region," said Thomas Karalis, Antengene's Corporate Vice President, Head of Asia Pacific Region. "In a region ....

South Korea , Hong Kong , Asia Pacific , Peter Qian , Jay Mei , Thomas Karalis , Antengene Corporation Limited , Hong Kong Stock Exchange , Karyopharm Therapeutics Inc , Company Annual , Indonesia National Agency Of Drug , New Drug Applications , Indonesia National Agency , Food Control , Corporate Vice President , Karyopharm Therapeutics , Corporation Limited , Patients Beyond , Taiwan China , Annual Report , Hong Kong Stock , Shanghai And Hong Kong , May 17 , 023 Prnewswire Antengene Corporation Limited Quot Sehk 6996 Hk , A Leading Innovative , Ommercial Stage Global Biopharmaceutical Company Dedicated To Discovering ,

Antengene Unveils Its First Australian Office to Continue Expanding Global Presence

SHANGHAI and HONG KONG, Sept. 14, 2022 /PRNewswire/ Antengene recently unveiled a new office space situated in Melbourne, Australia's most sought-after CBD, taking another important step in the company's continued global expansion. The new office offers an appealing environment that will help Antengene to attract more top talents, and further accelerate its expansion in the APAC region as well as its committed efforts to bring high quality and affordable innovative medicines to patients with life-threatening conditions including hematologic malignancies and solid tumors in Asia Pacific region and around the world. Occupying a space of 250 square meters in a Grade A office building in Melbourne's CBD that has an impressive 4.5-star NABERS energy rating and a 5.5-star NABERS water rating, the new office provides the fast-growing Australian team a superb work environment boasting a bird view of the downtown CBD area. In addition, the office has adopted a modern design with a ....

Hong Kong , South Korea , Thomas Karalis , Asia Pacific , Peter Qian , Michele Robbins , Company Annual , Antengene Corporation , Australia Therapeutic Goods Administration , Hong Kong Stock Exchange , Antengene Corporation Limited , Antengene Head Of Medical Affairs , Business Development , Pharmaceutical Benefits Scheme , Medical Affairs , Corporate Vice President , Asia Pacific Region , Senior Director , Tamara Etto , Corporation Limited , Patients Beyond , Greater China , Annual Report , Hong Kong Stock , Shanghai And Hong Kong , Sept 14 ,

Antengene Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

SHANGHAI and HONG KONG, June 8, 2022 /PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announcedthat the first patient has been dosed in the Phase I STAMINA-001 trial to evaluate ATG-037 as a monotherapy or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors in Australia. The primary objective of the study is to evaluate the safety, tolerability, recommended Phase II dose and preliminary antitumor efficacy of ATG-037 as a monotherapy and in combination with pembrolizumab. Secondary objectives include characterization of the pharmacology of ATG-037. ATG-037 is an orally available, small molecule CD73 inhibitor. CD73 is an "immune checkpoint mediator"1 that interferes with anti-tumor immune resp ....

United States , Hong Kong , South Korea , South Australia , Ganessan Kichenadasse , Kevin Lynch , Asia Pacific , Peter Qian , American Association Of Cancer Research Annual Meeting , Company Annual , Antengene Corporation , Hong Kong Stock Exchange , Antengene Corporation Limited , Southern Oncology Clinical Research Unit , Chief Medical , Cancer Research Annual Meeting , Corporation Limited , Patients Beyond , Greater China , Annual Report , Hong Kong Stock , Shanghai And Hong Kong , June 8 , 022 Prnewswire Antengene Corporation Limited Quot Sehk 6996 Hk , A Leading Innovative , Ommercial Stage Global Biopharmaceutical Company Dedicated To Discovering ,

Acciones de Evergrande volvieron a caer y el riesgo de default mantiene en vilo a los mercados

El temor por el impacto negativo que puede significar para los mercados del mundo un colapso chino impidió que las principales bolsas globales recuperaran una porción importante de lo perdido el lunes. ....

France General , Hong Kong , Deutsche Bank , Dow Jones , Hui The , Evergrande Will Come , Shanghai And Hong Kong , State Owned , Sector Rose , ஹாங் காங் , கருப்பு பாறை , டாய்ச் வங்கி , டோ ஜோன்ஸ் , ஹுய் தி , நிலை ஓஂட் ,